Correlations of systemic blood cytokines in patients with coronary heart disease and experienced COVID-19

DOI: https://doi.org/10.29296/25877305-2023-11-13
Issue: 
11
Year: 
2023

V. Negrebetsky(1); Professor N. Agarkov(2), MD; D. Shmarova(2)
1-N.I. Pirogov Russian National Research Medical University, Ministry of Health
of Russia, Moscow
2-Southwest State University, Ministry of Science and Higher Education of Russia, Kursk

Coronavirus infection brings an extreme threat to older people and particularly to patients with severe cardiovascular pathology, including coronary heart disease (CHD). Recovery in these patients largely depends on the severity of cytokine disorders in the acute phase of the disease, since they negatively affect cardiomyocytes, including those through the development of complications in other organs and systems. However, changes in the plasma cytokines of elderly patients with CHD who have experienced COVID-19 have not been studied in practice. Objective. To study the correlations of plasma cytokines in older patients with CHD in the early recovery stages after COVID-19. Subjects and methods. The investigation enrolled 40 elderly patients with CHD at weeks 3-4 following recovery from COVID-19 and 38 patients of the same age with CHD without COVID-19 in their history. The fasting plasma cytokine level was determined using a Becton Dickinson FACS Canto 2 apparatus (USA) in the morning. The relations between the cytokines were studied by the correlation method. Results. Interleukin (IL)-6 showed the greatest number of significant correlations (direct weak and medium associations with other cytokines), including a direct statistically significant average correlation with IL-17 (r=0.63), tumor necrosis factor-α (TNF-α) (r=0.42), interferon-γ (IFN-γ) (r=0.39), IL-2 (r=0.35), IL-3 (r=0.33), as well as a weak significant relationship to IL-7 (r=0.29). IFN-γ had three direct significant correlations with IL-6 (r=0.39), IL-7 (r=0.36), and TNF-α (r=0.29). The latter showed two direct average significant correlations with IL-6 and IL-17. Conclusion. In the early stages of recovery, in 60–74-year old patients with CHD after experienced COVID-19, IL-6, IFN-γ, and TNF-α cytokines had the greatest conjugacy, which can be used as markers of recovery in this patient cohort.
Keywords: 
cardiology
infectious diseases
coronary heart disease
coronavirus infection
blood cytokines
elderly patients
correlation analysis
early recovery periods.

References: 
  1. Толпыгина С.Н., Загребельский А.В., Марцевич С.Ю. Прогностическое значение кальцинированного аортального стеноза у пациентов регистра прогноз ИБС. Российский кардиологический журнал. 2022; 27 (1): 42–7 [Tolpygina S.N., Zagrebelsky A.V., Martsevich S.Yu. Prognostic value of calcified aortic stenosis in patients with IHD prognosis. Russian Journal of Cardiology. 2022; 27 (1): 42–7 (in Russ.)]. DOI: 10.15829/1560-4071-2022-4836
  2. Клесова Е.Ю., Азарова Ю.Э., Суняйкина О.А. и др. Валидация краткого опросника для оценки вклада средовых факторов риска в развитие возраст-зависимых заболеваний на примере сахарного диабета 2 типа и ишемической болезни сердца. Научные результаты биомедицинских исследований. 2022; 8 (1): 130–8 [Klesova E.Yu., Azarova Yu.E., Sunyakina O.A. et al. Validation of a short questionnaire to assess the contribution of environmental risk factors to the development of age-dependent diseases on the example of type 2 diabetes mellitus and coronary heart disease. Research Results in Biomedicine. 2022; 8 (1): 130–8 (in Russ.)]. DOI: 10.18413/2658-6533-2022-8-1-0-10
  3. Yang L., Wang L., Deng Y. et al. Serum lipids profiling perturbances in patients with ischemic heart disease and ischemic cardiomyopathy. Lipids Health Dis. 2020; 19 (1): 89. DOI: 10.1186/s12944-020-01269-9
  4. Bauersachs R., Zeymer U., Briere J.B. et al. Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review. Cardiovasc Ther. 2019; 2019: 8295054. DOI: 10.1155/2019/8295054
  5. Марцевич С.Ю., Кутишенко Н.П., Лукьямов М.М. и др. Госпитальный регистр больных, перенесших острое нарушение мозгового кровообращения (регион): портрет заболевшего и исходы стационарного этапа лечения. Кардиоваскулярная терапия и профилактика. 2018; 17 (6): 32–8 [Martsevich S.Yu., Kutishenko N.P., Lukyanov M.M. et al. Hospital register of patients with acute cerebrovascular accident (region): portrait of the patient and outcomes of the inpatient stage of treatment. Cardiovascular therapy and prevention. 2018; 17 (6): 32–8 (in Russ.)]. DOI: 10.15829/1728-8800-2018-6-32-38
  6. Oldroyd K.G., Rush C.J., Berry C. et al. Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021; 6 (10): 1130–43. DOI: 10.1001/jamacardio.2021.1825
  7. Агарков Н.М., Макконен К.Ф., Титов А.А. и др. Иммунный плейотропный эффект телмисартана при артериальной гипертензии. Медицинская иммунология. 2022; 24 (4): 831–6 [Agarkov N.M., Makkonen K.F., Titov A.A. et al. Immune pleiotropic effect of telmisartan in arterial hypertension. Medical immunology (Russia). 2022; 24 (4): 831–6 (in Russ.)]. DOI: 10.15789/1563-0625-IPE-2476
  8. Clarke R., Valses-Marquez E., Hill M. et al. Plasma cytokines and risk of coronary heart disease in the PROCARDIS study. Open Heart. 2018; 5 (1): е000807. DOI: 10.1136/openhrt-2018-000807
  9. Moccia F., Gerbino A., Lionetti V. et al. COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. Geroscience. 2020; 42 (4): 1021–49. DOI: 10.1007/s11357-020-00198-w
  10. Shafeghat M., Aminorroaya A., Rezaei N. How Stable Ischemic Heart Disease Leads to Acute Coronary Syndrome in COVID-19? Acta Biomed. 2021; 92 (5): е2021512. DOI: 10.23750/abm.v92i5.12013
  11. Арсентьева Н.А., Любимова Н.Е., Бацунов О.К. и др. Цитокины в плазме крови больных COVID-19 в острой фазе заболевания и фазе полного выздоровления. Медицинская иммунология. 2021; 23 (2): 311–26 [Arsentieva N.A., Lyubimova N.E., Batsunov O.K. et al. Cytokines in the blood plasma of COVID-19 patients in the acute phase of the disease and the phase of full recovery. Medical immunology (Russia). 2021; 23 (2): 311–26 (in Russ.)]. DOI: 10.15789/1563-0625-PCI-2312
  12. Laing A.G., Lorenc A., Barrio I.D. et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. J Nat Med. 2020; 26 (10): 1623–35. DOI: 10.1038/s41591-020-1038-6
  13. Zhang H., Li X., Li X. et al. Circulating Cytokines and Lymphocyte Subsets in Patients Who Have Recovered from COVID-19. Biomed Res Int. 2020; 2020: 7570981. DOI: 10.1155/2020/7570981
  14. Беляева В.А. Патогенетические механизмы повреждения миокарда при COVID-19. Современные проблемы науки и образования. 2021; 6: 192 [Belyaeva V.A. Pathogenetic mechanisms of myocardial damage in COVID-19. Modern problems of science and education. 2021; 6: 192 (in Russ.)]. DOI: 10.17513/spno.31299